Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Recurrent Pericarditis
Interventions
VTX2735
Drug
Lead sponsor
Zomagen Biosciences Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
17
States / cities
Tucson, Arizona • Orange, California • Saint Augustine, Florida + 13 more
Conditions
Pericarditis, Pericarditis Acute, Recurrent Pericarditis
Interventions
KPL-387, Placebo
Drug
Lead sponsor
Kiniksa Pharmaceuticals International, plc
Industry
Eligibility
18 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
27
States / cities
Gilbert, Arizona • Phoenix, Arizona • Los Angeles, California + 22 more
Conditions
Recurrent Pericarditis
Interventions
RPH-104, Placebo
Biological · Drug
Lead sponsor
R-Pharm Overseas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Recurrent Pericarditis
Interventions
Not listed
Lead sponsor
Kiniksa Pharmaceuticals International, plc
Industry
Eligibility
7 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
29
States / cities
Anchorage, Alaska • Tucson, Arizona • La Jolla, California + 23 more
Conditions
Recurrent Pericarditis
Interventions
CardiolRx
Drug
Lead sponsor
Cardiol Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • Boston, Massachusetts + 5 more
Conditions
Recurrent Pericarditis, Heart Diseases, Pericarditis
Interventions
KPL-387
Drug
Lead sponsor
Kiniksa Pharmaceuticals International, plc
Industry
Eligibility
18 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 11 more
Conditions
Recurrent Pericarditis
Interventions
CardiolRx
Drug
Lead sponsor
Cardiol Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 16 more
Completed Phase 2 Interventional Results available

A Pilot Study of KPL-914 in Recurrent Pericarditis

NCT03980522
Conditions
Recurrent Pericarditis
Interventions
KPL-914
Drug
Lead sponsor
Kiniksa Pharmaceuticals (UK), Ltd.
Industry
Eligibility
6 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Washington D.C., District of Columbia • DeLand, Florida • Jacksonville, Florida + 11 more
Conditions
Recurrent Pericarditis
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
Kiniksa Pharmaceuticals (UK), Ltd.
Industry
Eligibility
12 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
12
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 9 more